欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01477 欧康维视生物-B

休市中 04-24 16:08:27

7.500

-0.100

-1.32%

最高7.800	最低7.390	成交量44.85万
今开7.800	昨收7.600	日振幅5.39%
总市值61.13亿	流通市值61.13亿	总股本8.15亿
成交额336.93万	换手率0.06%	流通股本8.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":7.5,"timestamp":1777018107003,"preClose":7.6,"halted":0,"volume":448500,"delay":0,"changeRate":-0.01315789473684206,"floatShares":815000000,"shares":815000000,"eps":-0.22923542224938492,"marketStatus":"休市中","change":-0.1,"latestTime":"04-24 16:08:27","open":7.8,"high":7.8,"low":7.39,"amount":3369305,"amplitude":0.053947,"askPrice":7.52,"askSize":500,"bidPrice":7.46,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.22923542224938492,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777253400000},"marketStatusCode":7,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":7.6,"openAndCloseTimeList":[[1776994200000,1777003200000],[1777006800000,1777017600000]],"volumeRatio":0.5195316084267191,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477","defaultTab":"news","newsList":[{"id":"2629894566","title":"创新药概念持续拉升 海西新药(02637)领涨12.77%、歌礼制药-B(01672)涨6.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629894566","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629894566?lang=zh_cn&edition=full","pubTime":"2026-04-24 13:11","pubTimestamp":1777007494,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念午后集体持续拉升，截至发稿，海西新药 涨12.77%，歌礼制药-B涨6.27%，诺诚健华涨5.18%，信达生物涨4.10%，科伦博泰生物涨2.84%，亚盛医药-B涨2.79%。西南证券亦表示，医药生物行业近期表现虽相对疲软，估值溢价率有所下降，但行业整体仍保持一定韧性。其他生物制品、医疗研发外包和原料药等细分领域表现突出，显示出医药创新和产业链优势的持续释放。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979909","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","01672","LU2328871848.SGD","LU0502904849.HKD","06978","LU2488822045.USD","BK1515","HK0000165453.HKD","LU2097828557.USD","LU2097828474.EUR","06990","159992","BK1583","BK1191","LU2097828805.USD","01801","BK1161","01477","LU0455707207.USD","LU2097828631.EUR","LU2242644610.SGD","BK1589","06855","LU1969619763.USD","02637","BK1574","09969","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629896382","title":"港股异动 | 歌礼制药-B(01672)午前涨超4% 核心管线ASC30即将启动III期注册临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2629896382","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629896382?lang=zh_cn&edition=full","pubTime":"2026-04-24 11:10","pubTimestamp":1777000213,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，歌礼制药-B午前涨超4%，截至发稿，涨3.46%，报18.82港元，成交额2199.1万港元。消息面上，歌礼制药此前宣布启动ASC30_39FDC的临床开发，并计划于今年第三季度向美国FDA递交IND申请。口服剂型即将向FDA提交III期临床计划，公司预计将在2026年Q3正式启动。值得注意的是，智通财经APP在《歌礼制药-B：股价突破前高在即，场外资金为何选择观望？》中指出，礼来Orforglipron已于今年4月1日获FDA批准上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1574","III","BK1191","VXUS","BK4134","01477","01672","BK1161","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629830726","title":"泽璟制药（688266）披露将参加2025年度制药行业集体业绩说明会，4月23日股价下跌3.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629830726","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629830726?lang=zh_cn&edition=full","pubTime":"2026-04-23 22:05","pubTimestamp":1776953123,"startTime":"0","endTime":"0","summary":"截至2026年4月23日收盘，泽璟制药报收于98.0元，较前一交易日下跌3.14%，最新总市值为259.41亿元。近日，泽璟制药发布《关于参加十五五·科创惠民——科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明会的公告》。公告显示，公司将于2026年5月11日15:00-17:00通过上证路演中心网络互动方式参加由上海证券交易所主办的上述集体业绩说明会。公司将就2025年年度报告涉及的经营成果、财务状况等投资者关注问题进行解答。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300061779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1191","BK0239","688266","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629022259","title":"艾伯维斥资14亿美元在北卡罗来纳州建制药园区","url":"https://stock-news.laohu8.com/highlight/detail?id=2629022259","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629022259?lang=zh_cn&edition=full","pubTime":"2026-04-23 03:32","pubTimestamp":1776886320,"startTime":"0","endTime":"0","summary":"2026年4月22日，全球生物制药巨头艾伯维公司宣布了一项重大投资计划，将斥资14亿美元在美国北卡罗来纳州达勒姆市建设一个全新的制药制造园区。这是该公司迄今为止在单一地点进行的最大规模投资。　　根据规划，这座占地185英亩的新园区将成为艾伯维在美国主要的注射药物生产基地，旨在扩大其国内产能，以满足全球市场对关键药物的需求。　　此项投资是艾伯维未来十年在美国投入约1000亿美元用于研发和制造宏伟计划的重要组成部分。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-23/doc-inhvmmmn5225636.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629700085","title":"凯莱英：拥有连续性反应等核心制药技术的自主知识产权","url":"https://stock-news.laohu8.com/highlight/detail?id=2629700085","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629700085?lang=zh_cn&edition=full","pubTime":"2026-04-21 15:54","pubTimestamp":1776758052,"startTime":"0","endTime":"0","summary":"证券之星消息，凯莱英04月21日在投资者关系平台上答复投资者关心的问题。公司拥有连续性反应等核心制药技术的自主知识产权，是世界上为数不多的将连续性反应技术延伸应用在大规模生产制造的公司之一，并持续提升连续性反应以及各项新技术在临床中后期项目中的应用率。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100033830.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","002821","BK0239","BK1191","LU1328615791.USD","06821","01477","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628745559","title":"科伦药业：公司持有海南普利制药股份有限公司股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2628745559","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628745559?lang=zh_cn&edition=full","pubTime":"2026-04-20 17:00","pubTimestamp":1776675628,"startTime":"0","endTime":"0","summary":"证券之星消息，科伦药业(002422)04月20日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司是持有普利制药股票还是债券？谢谢科伦药业回复：投资者您好，公司持有海南普利制药股份有限公司股权。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000022697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1979443071.USD","BK1191","LU1064130708.USD","LU1064131003.USD","BK0060","BK1574","01477","BK0239","LU1934453819.USD","002422","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628711742","title":"制药界的Space X来了，剂泰科技通过聆讯，冲刺“AI药物递送第一股”","url":"https://stock-news.laohu8.com/highlight/detail?id=2628711742","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628711742?lang=zh_cn&edition=full","pubTime":"2026-04-20 14:10","pubTimestamp":1776665407,"startTime":"0","endTime":"0","summary":"一个不同于靶点发现的叙事样本","market":"sh","thumbnail":"https://img2.gelonghui.com/6c8ee-bf7bb5e5-3101-4faa-8201-46ed154478bd.jpg?guru_height=855&guru_width=1458&guru_size=220020","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/6c8ee-bf7bb5e5-3101-4faa-8201-46ed154478bd.jpg?guru_height=855&guru_width=1458&guru_size=220020"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4473843","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1574","01477","AGIX","AIPO","CHAT","ARTY","BK1191","SOCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628679061","title":"新股解读 ｜ 制药界“SpaceX”启航：AI药物递送第一股，剂泰科技开启生物制药递送时代","url":"https://stock-news.laohu8.com/highlight/detail?id=2628679061","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628679061?lang=zh_cn&edition=full","pubTime":"2026-04-20 09:16","pubTimestamp":1776647792,"startTime":"0","endTime":"0","summary":"在这一背景下，剂泰科技于近日正式通过港交所聆讯，作为“全球AI药物递送第一股”，剂泰科技的出现不仅是AI制药赛道的一个里程碑，更标志着人工智能对生物医药的赋能已经从分子发现延伸到了更为底层、更具壁垒的大分子递送领域。打造制药界的“SpaceX”与底层系统供应商在商业化逻辑上，剂泰科技采取了“平台合作+管线授权”双轨并行的商业模式，旨在实现价值最大化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","UFO","ARTY","AGIX","DXYZ","BK1191","CHAT","XOVR","01477","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628536739","title":"歌礼制药-B(01672)：股价突破前高在即，场外资金为何选择观望？","url":"https://stock-news.laohu8.com/highlight/detail?id=2628536739","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628536739?lang=zh_cn&edition=full","pubTime":"2026-04-18 12:36","pubTimestamp":1776486970,"startTime":"0","endTime":"0","summary":"股价突破前高在即，场外资金却选择观望?但在3月30日，歌礼制药交出2025年成绩单后，二级市场却出现“三连阴”放缓了公司股价后续的上攻势头。导致歌礼制药在2025年“增收不增利”的主要原因在于当期研发费用暴增。并且根据最新信息，礼来Orforglipron已于今年4月1日获FDA批准上市，成为全球首个口服小分子非肽类GLP-1减重药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430290.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","01672","BK1191","BK1515","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628927838","title":"港股异动 | 歌礼制药-B(01672)午后涨近5% 股价逼近历史前高 GLP-1+胰淀素复方制剂启动临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2628927838","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628927838?lang=zh_cn&edition=full","pubTime":"2026-04-17 14:28","pubTimestamp":1776407328,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，歌礼制药-B午后涨近5%，高见18.68港元，逼近历史前高18.75港元。消息面上，歌礼制药近日公告，口服小分子GLP-1受体激动剂与口服小分子胰淀素受体激动剂固定剂量复方制剂ASC30_39FDC全面启动临床开发。值得关注的是，这是全球首个公开宣布的口服小分子GLP-1与口服小分子胰淀素固定剂量复方制剂，标志着歌礼在代谢疾病领域的创新布局实现关键突破。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429849.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01672","01477","BK1161","BK1574","BK1191","BK4588","GLP","VXUS","BK4144","BK1515","BK4590","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628221164","title":"港股异动 | CXO 概念股跌幅居前 海外投融资大环境进入波动阶段 AI制药或导致研发及临床端分化","url":"https://stock-news.laohu8.com/highlight/detail?id=2628221164","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628221164?lang=zh_cn&edition=full","pubTime":"2026-04-17 11:31","pubTimestamp":1776396664,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，CXO概念股跌幅居前，截至发稿，昭衍新药跌5.82%，报21.7港元；康龙化成跌3.65%，报21.1港元；泰格医药跌3.02%，报42.46港元。中信建投发布研报称，海外投融资大环境进入季度间波动，不同阶段、不同疾病领域的CXO服务需求进一步分化，国内投融资活动景气度持续上行，弹性更强，持续看好CXO板块成长空间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","03759","BK4588","CXO","BK1574","01477","06127","AIPO","ARTY","BK1576","BK4585","BK1583","BK1191","CHAT","VXUS","AGIX","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627293848","title":"印度Hetero制药司美格鲁肽笔全球推广目标年销量150万支","url":"https://stock-news.laohu8.com/highlight/detail?id=2627293848","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627293848?lang=zh_cn&edition=full","pubTime":"2026-04-16 16:44","pubTimestamp":1776329040,"startTime":"0","endTime":"0","summary":"　　印度大型私营制药企业之一 Hetero 实验室公司一名高管表示，该公司计划未来数年在超 75 个国家推出仿制版减肥及糖尿病药物，首年目标销量达 150 万支注射笔。　　Hetero 董事总经理瓦姆西克里希纳班迪 3 月接受路透社采访时称，公司计划 4 月在印度本土上市该药物，初期将重点拓展海外市场份额。　　其规模更大的竞争对手雷迪博士实验室已宣布，首年目标销量为 1200 万支；而 MSN 实验室等中小型药企则计划在印度本土首年实现 10 万支的销量目标。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-16/doc-inhusvke3927022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MNDmain","BK1191","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627265276","title":"关怀老人儿童，在沪外企捐赠190箱爱心物资","url":"https://stock-news.laohu8.com/highlight/detail?id=2627265276","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627265276?lang=zh_cn&edition=full","pubTime":"2026-04-16 12:51","pubTimestamp":1776315060,"startTime":"0","endTime":"0","summary":"为践行“创造精彩生活”理念，日前小林制药（中国）以公益行动回馈社会小林制药（中国）有限公司携手上海市慈善基金会向本多家养老院、幼儿园等机构捐赠了一批爱心物资。《关怀老人儿童，在沪外企捐赠190箱爱心物资》栏目编辑：顾莹颖 题图来源：受访者供图 图片来源：受访者供图 来源：作者：新民晚报 李一能","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-04-16/doc-inhuskuh7266988.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01477","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627328922","title":"“AI制药第一股”晶泰科技进驻广州天河","url":"https://stock-news.laohu8.com/highlight/detail?id=2627328922","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627328922?lang=zh_cn&edition=full","pubTime":"2026-04-15 19:30","pubTimestamp":1776252617,"startTime":"0","endTime":"0","summary":"4月15日，AI制药领军企业、“AI制药第一股”晶泰科技正式进驻广州天河的广电平云广场，同时与广州数字科技集团、广东创新投资发展有限公司完成战略签约，共同推动医疗数据与垂类大模型在生物医药领域深度应用。同日，平云OPC创新社区挂牌。晶泰科技由三位麻省理工学院的物理学家于2015年创立，是全球领先的以AI与机器人自动化实验技术驱动研发创新的平台型企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153706140328.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153706140328.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1617","AIPO","BK1574","AGIX","01477","BK1141","BK1191","ARTY","02228","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627288322","title":"科伦药业：公司出于战略目的而计划长期持有海南普利制药股份有限公司股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2627288322","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627288322?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:39","pubTimestamp":1776245949,"startTime":"0","endTime":"0","summary":"证券之星消息，科伦药业(002422)04月15日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司持有2000多万的普利制药，都已经退市了 ，为什么还高位买进科伦药业回复：投资者您好，公司出于战略目的而计划长期持有海南普利制药股份有限公司股权。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500031987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK0060","LU1979443071.USD","002422","BK1574","LU2148510915.USD","LU1934453819.USD","01477","BK1191","BK0239","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627548730","title":"科源制药：力诺制药与江苏赛邦药业有限公司诉讼案件目前已进入二审阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2627548730","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627548730?lang=zh_cn&edition=full","pubTime":"2026-04-13 15:00","pubTimestamp":1776063639,"startTime":"0","endTime":"0","summary":"证券之星消息，科源制药(301281)04月12日在投资者关系平台上答复投资者关心的问题。投资者提问：公司现在和赛邦的进展如何，未来如何拓展渠道？科源制药回复：尊敬的投资者您好，公司全资子公司力诺制药与江苏赛邦药业有限公司诉讼案件目前已进入二审阶段，力诺制药将积极维护自身合法权益。如有相关进展，将会根据监管规则进行公告，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300013067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301281","BK1191","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627483534","title":"华创证券：AI制药进入快速发展阶段 从概念验证向商业化兑现转变","url":"https://stock-news.laohu8.com/highlight/detail?id=2627483534","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627483534?lang=zh_cn&edition=full","pubTime":"2026-04-13 10:34","pubTimestamp":1776047676,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华创证券发布研报称，中国AI制药市场开始进入快速发展阶段，2024年市场规模达到5.6亿元，同比增长36.59%，2025年市场规模突破6亿元。多维度利好共振推动AI制药进入快速发展通道。AI制药行业正处于从概念验证向商业化兑现转变的关键阶段，建议重点关注具有平台技术优势、临床管线进展积极、商业模式清晰的优质标的。2021年市场规模增速明显提升，达到100%，表明了中国AI制药市场开始进入快速发展阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ARTY","BK1574","BK1191","CHAT","161027","AGIX","AIPO","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182346468","title":"欧康维视生物-B 3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1182346468","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182346468?lang=zh_cn&edition=full","pubTime":"2026-04-08 19:05","pubTimestamp":1775646337,"startTime":"0","endTime":"0","summary":"欧康维视生物-B于2026年4月8日发布截至2026年3月31日的股份变动月报。公告显示，公司本月注册股本保持5,000,000,000股，面值每股USD 0.00001，注册股本总额USD 50,000，与上月持平。2018年员工购股权计划仍维持13,317,816份未行使期权。2021年购股权计划由37,591,614份减少至37,524,567份，减少原因为期权失效67,047份，其中并未有行使或发行新股。公告显示，公司确认遵守香港联交所《上市规则》及相关法律规定。截至2026年3月31日，公司股份总数维持不变，股本结构总体稳定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625627937","title":"歌礼制药-B(01672)：每日一次口服小分子GLP-1R激动剂ASC30与每日一次口服小分子胰淀素选择性胰淀素受体激动剂ASC39的固定剂量复方制剂进行临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2625627937","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625627937?lang=zh_cn&edition=full","pubTime":"2026-04-07 19:34","pubTimestamp":1775561655,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，董事会宣布已选定ASC30_39 FDC，即每日一次口服小分子GLP-1R激动剂ASC30与每日一次口服小分子胰淀素选择性胰淀素受体激动剂ASC39的固定剂量复方制剂，进行临床开发。“据我们所知，这是首个公开宣布的口服GLP-1与口服胰淀素复方制剂，选定这一固定剂量复方制剂是开发ASC30与ASC39新型潜在协同口服复方制剂治疗肥胖的重要一步。”","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4590","01477","BK1191","BK4144","BK1161","BK1574","BK1515","GLP","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624512846","title":"药闻 | 英硅智能再落地重磅合作  AI制药行业较量从拼算法转向拼验证与数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2624512846","media":"新华财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624512846?lang=zh_cn&edition=full","pubTime":"2026-04-03 18:10","pubTimestamp":1775211002,"startTime":"0","endTime":"0","summary":"新华财经上海4月3日电（记者杜康）继去年底登陆港交所以来，英硅智能在对外授权和跨国药企合作上动作频频。日前，这家由生成式人工智能驱动的生物医药科技公司宣布，与礼来达成总价值最高可达约27.5亿美元的药物发现合作，将利用其AI引擎加速多个治疗领域新型疗法的发现与开发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604033695067135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","ARTY","AGIX","BK1191","CHAT","01477","AIPO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocumension.com","stockEarnings":[{"period":"1week","weight":-0.092},{"period":"1month","weight":0.0669},{"period":"3month","weight":0.0331},{"period":"6month","weight":-0.1018},{"period":"1year","weight":0.3562},{"period":"ytd","weight":0.0135}],"compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":0.0253},{"period":"3month","weight":-0.0288},{"period":"6month","weight":-0.007},{"period":"1year","weight":0.1857},{"period":"ytd","weight":0.0136}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家主要从事眼科药物的研发和商业化的公司。该公司产品主要包括OT-401“优施莹”氟轻松玻璃体内植入剂、OT-702“博优景”阿柏西普眼内注射溶液、OT-402“维速达尔”注射用维替泊芬、OT-204“欧沁”玻璃酸钠滴眼液及OT-305“贝特舒”盐酸倍他洛尔滴眼液等。该公司产品主要用于治疗葡萄膜炎、眼底疾病、屈光矫正、干眼症（DED）、青光眼及角结膜炎等各种眼前及眼后段疾病。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.097698},{"month":2,"riseRate":0.5,"avgChangeRate":-0.037557},{"month":3,"riseRate":0.5,"avgChangeRate":0.044668},{"month":4,"riseRate":0.5,"avgChangeRate":0.017903},{"month":5,"riseRate":0.6,"avgChangeRate":0.137077},{"month":6,"riseRate":0.8,"avgChangeRate":0.129408},{"month":7,"riseRate":0.4,"avgChangeRate":-0.027707},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.064893},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.082685},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.121217},{"month":11,"riseRate":0.333333,"avgChangeRate":0.004503},{"month":12,"riseRate":0.5,"avgChangeRate":0.058088}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}